Rose McNulty


Understanding Real-World Trends in MRD Testing as Part of MM Management

January 18, 2022

An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.